Back to Search Results

3/1/2016

Management of Large Rectoceles in Geriatric Patients

Author: Anne Garrison, MD

Mentor: Tiffany Moore-Simas, MD
Editor: Julie Decesare, MD

Registered users can also download a PDF or listen to a podcast of this Pearl.
Log in now, or create a free account to access bonus Pearls features.

Patients with rectoceles may be asymptomatic or have symptoms such as splinting, pelvic pressure, dyspareunia, constipation, fecal incontinence, and defecatory dysfunction. Rectocele extent does not necessarily correlate with the severity of symptoms.

No treatment is required for asymptomatic or mildly symptomatic elderly patients. Effective management of constipation is important.  Treatment is necessary if hydronephrosis, non-resolving vaginal erosions, or obstruction develop.

Nonsurgical treatment options should be discussed. Pelvic examination should assess the extent of prolapse in all compartments and include rectovaginal exam, assessment of the anal sphincter, and neurologic evaluation of the area.  A pessary can be offered regardless of prolapse stage. Numerous vaginal pessaries are available and data do not support one type of pessary over another for women with rectoceles.

Pelvic floor muscle rehabilitation and symptom-directed therapy may be offered. Pelvic floor physical therapy is typically performed once or twice weekly over a 2 to 3 month period, supervised by an experienced therapist or practitioner. 

Indications for surgical management include desire for definitive correction, difficulty with intercourse, recurrent ulcerations from pessary use, or unacceptable incontinence. Decision to perform surgery must balance the surgical risks against the potential benefits. Perioperative risk is increased in older patients with concomitant medical problems and careful preoperative assessment and management of identified conditions should be performed. Pre-operative defect assessment including evaluation for presence of co-existing enterocele, sigmoidocele, and apical defects can inform the surgical approach. Dyspareunia should be assessed in sexually active patients.

There is no consensus regarding the optimal surgical approach. Historically, the primary surgical therapy is posterior colporrhaphy, often including a perineorrhaphy. The surgeon should maintain adequate vaginal caliber for sexually active patients. Plication of the levator ani muscles may also be performed. Other techniques include defect-directed repair and posterior fascial replacement via transanal, laparoscopic, and abdominal approaches. Obliterative procedures (colpocleisis) can be offered to women at high risk for complications with reconstructive procedures who do not desire vaginal intercourse.

In April 2019, the FDA ordered the complete cessation of selling and distributing mesh products designed to treat pelvic organ prolapse after they determined that placement of these devices did not demonstrate an acceptable risk-benefit profile compared with repairs performed using native tissue. Complications reported to the FDA for mesh prolapse repairs included mesh erosion and contraction, pain, infection, bleeding, dyspareunia, fistula, and vascular and organ injury.  Many complications required additional interventions including hospitalization and medical or surgical treatment.

Further Reading:

American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology and American Urogynecologic Society. Pelvic Organ Prolapse: ACOG Practice Bulletin, Number 214. Obstet Gynecol. 2019;134(5):e126-e142. doi:10.1097/AOG.0000000000003519

U.S. Food and Drug Administration. FDA takes action to protect women’s health, orders manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse to stop selling all devices. Silver Spring (MD): FDA; 2019. Available at: https://www.fda.gov/news-events/press-announcements/fda-takes-action-protect-womens-health-orders-manufacturers-surgical-mesh-intended-transvaginal, Retrieved August 20, 2020. 

Initial Approval:  January 16, Revised July 2017; Reaffirmed January 2019; Revised September 2020

 

********** Notice Regarding Use ************

The Society for Academic Specialists in General Obstetrics and Gynecology, Inc. (“SASGOG”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.

This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high-quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.

Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. SASGOG reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. SASGOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither SASGOG nor its respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

Copyright 2020 The Society for Academic Specialists in General Obstetrics and Gynecology, Inc. All rights reserved.  No re-print, duplication or posting allowed without prior written consent.

 

Back to Search Results